Cited by 229CAR-T cell therapy researchPharmaceutical Economics and PolicyEconomic and Financial Impacts of Cancer

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers

Prasad, Vinay·2018·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2017.156

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2017.156

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
Prasad, V. K., & Mailankody, S. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.3601 · Cited by 532
Self-citation
Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large National Private Claims Database
Majhail, N. S., Mau, L., Denzen, E. M., & Arneson, T. J. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.133 · Cited by 143
Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?
Lamont, E. B., Hayreh, D., Pickett, K. E., Dignam, J. J., List, M. A., Stenson, K. M., Haraf, D. J., Brockstein, B., Sellergren, S. A., & Vokes, E. E. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg035 · Cited by 139
Re: Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?
Munoz, A., & Samet, J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh065 · Cited by 112
FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome
Administration, U. S. F. &. D. (2017) · Case Medical Research · doi:10.31525/fda1-ucm574154.htm · Cited by 28

Show all 5 references

Research works printed but not linked: 2

Mitchell, D. Patients For Affordable Drugs launches campaign demanding fair pricing of new Novartis cancer drug. Patients For Affordable Drugs http://www.patientsforaffordabledrugs.org/2017/08/17/patients-for-affordable-drugs-launches-campaign-demanding-fair-pricing-of-new-cancer-drug/ (17 Aug 2017).
Gilead Sciences, Inc. Gilead Sciences to acquire Kite Pharma for $11.9 billion. Gilead Sciences, Inc. http://www.gilead.com/news/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion (28 Aug 2017).

Sorted by citations

The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions
Lu, P., Ruan, D., Huang, M., Tian, M., Zhu, K., Gan, Z., & Xiao, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01852-x · Cited by 762
Enabling Technologies for Personalized and Precision Medicine
Ho, D., Quake, S. R., McCabe, E. R. B., Chng, W. J., Chow, E. K., Ding, X., Gelb, B. D., Ginsburg, G. S., Hassenstab, J., Ho, C.-M., et al. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2019.12.021 · Cited by 517
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
Wang, S.-W., Gao, C., Zheng, Y.-M., Yi, L., Lu, J.-C., Huang, X.-Y., Cai, J.-B., Zhang, P.-F., Cui, Y.-H., & Ke, A.-W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01518-8 · Cited by 478
Engineering microrobots for targeted cancer therapies from a medical perspective
Schmidt, C. K., Medina‐Sánchez, M., Edmondson, R. J., & Schmidt, O. G. (2020) · Nature Communications · doi:10.1038/s41467-020-19322-7 · Cited by 452
The approved gene therapy drugs worldwide: from 1998 to 2019
Ma, C.-C., Wang, Z.-L., Xu, T., He, Z.-Y., & Wei, Y.-Q. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107502 · Cited by 310
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Biomaterials tools to modulate the tumour microenvironment in immunotherapy
Chao, Y., & Liu, Z. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00004-6 · Cited by 262
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Mahadeo, K. M., Khazal, S. J., Abdel‐Azim, H., Fitzgerald, J. C., Taraseviciute, A., Bollard, C. M., Tewari, P., Duncan, C., Traube, C., McCall, D. C., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0075-2 · Cited by 246
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment
Liu, G., Rui, W., Zhao, X., & Lin, X. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00655-2 · Cited by 244
Organ-on-a-Chip for Cancer and Immune Organs Modeling
Sun, W., Luo, Z., Lee, J., Kim, H., Lee, K., Tebon, P., Feng, Y., Dokmeci, M. R., Sengupta, S., & Khademhosseini, A. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801363 · Cited by 221
Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells
Agarwalla, P., Ogunnaike, E. A., Ahn, S., Froehlich, K. A., Jansson, A., Ligler, F. S., Dotti, G., & Brudno, Y. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01245-x · Cited by 216
Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
Dejenie, T. A., Medhin, M. T. G., Terefe, G. D., Admasu, F. T., Tesega, W. W., & Abebe, E. C. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2114254 · Cited by 210
CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies
Knochelmann, H. M., Smith, A. S., Dwyer, C. J., Wyatt, M. M., Mehrotra, S., & Paulos, C. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01740 · Cited by 188
Nanobody-based CAR-T cells for cancer immunotherapy
Kozani, P. S., Naseri, A., Mirarefin, S. M. J., Salem, F., Nikbakht, M., Bakhshi, S. E., & Kozani, P. S. (2022) · Biomarker Research · doi:10.1186/s40364-022-00371-7 · Cited by 189
CRISPR–Cas: a tool for cancer research and therapeutics
Yin, H., Xue, W., & Anderson, D. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0166-8 · Cited by 185
Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
Sheykhhasan, M., Manoochehri, H., & Dama, P. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00418-1 · Cited by 165
A new era of cancer phototherapy: mechanisms and applications
Wang, Y., Ma, K., Kang, M., Yan, D., Niu, N., Yan, S., Sun, P., Zhang, L., Sun, L., Wang, D., et al. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00708e · Cited by 162
CAR-NK Cells: From Natural Basis to Design for Kill
Khawar, M. B., & Sun, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.707542 · Cited by 164
Biological Products: Cellular Therapy and FDA Approved Products
Golchin, A., & Farahany, T. Z. (2019) · Stem Cell Reviews and Reports · doi:10.1007/s12015-018-9866-1 · Cited by 148
High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions
Cliff, E. R. S., Kelkar, A. H., Russler‐Germain, D. A., Tessema, F. A., Raymakers, A., Feldman, W. B., & Kesselheim, A. S. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_397912 · Cited by 150
Synthetic gene circuits for the detection, elimination and prevention of disease
Sedlmayer, F., Aubel, D., & Fussenegger, M. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0215-0 · Cited by 143
Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments
Sandomenico, A., Sivaccumar, J. P., & Ruvo, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176324 · Cited by 134
Harnessing the chemokine system to home CAR-T cells into solid tumors
Foeng, J., Comerford, I., & McColl, S. R. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100543 · Cited by 133
Vascular Microenvironment, Tumor Immunity and Immunotherapy
Lamplugh, Z. L., & Fan, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.811485 · Cited by 131
Circular Bispecific Aptamer-Mediated Artificial Intercellular Recognition for Targeted T Cell Immunotherapy
Yang, Y. P., Sun, X., Xu, J., Cui, C., Yazd, H. S., Pan, X., Zhu, Y., Chen, X., Li, X., Li, J., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b09884 · Cited by 112
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
Vairy, S., Garcia, J. L., Teira, P., & Bittencourt, H. N. D. S. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s138765 · Cited by 112
Cost of decentralized CAR T‐cell production in an academic nonprofit setting
Ran, T., Eichmüller, S. B., Schmidt, P., & Schlander, M. (2020) · International Journal of Cancer · doi:10.1002/ijc.33156 · Cited by 118
In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
Xin, T., Li, C., Zhou, C., Zhao, Y., Hu, Z., & Wu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.809754 · Cited by 115
Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Hosseinkhani, N., Derakhshani, A., Kooshkaki, O., Shadbad, M. A., Hajiasgharzadeh, K., Baghbanzadeh, A., Safarpour, H., Mokhtarzadeh, A., Brunetti, O., Yue, S. C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218305 · Cited by 116
Imaging of tumour response to immunotherapy
Dromain, C., Beigelman‐Aubry, C., Pozzessere, C., Durán, R., & Digklia, A. (2020) · European Radiology Experimental · doi:10.1186/s41747-019-0134-1 · Cited by 99
Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways
Yang, Y., Badeti, S., Hsiang-Chi, T., Ma, M. T., Liu, T., Jiang, J., Liu, C., & Liu, D. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.014 · Cited by 96
Engineering chimeric antigen receptor-T cells for cancer treatment
Ye, B., Stary, C. M., Li, X., Gao, Q., Kang, C., & Xiong, X. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0814-0 · Cited by 95
Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy
Han, J., Lim, J., Wang, C. J., Han, J., Shin, H. E., Kim, S.-N., Jeong, D., Lee, S. H., Chun, B.-H., Park, C. G., et al. (2023) · Nano Convergence · doi:10.1186/s40580-023-00385-3 · Cited by 100
Engineering Precision Medicine
Sun, W., Lee, J., Zhang, S., Benyshek, C., Dokmeci, M. R., & Khademhosseini, A. (2018) · Advanced Science · doi:10.1002/advs.201801039 · Cited by 96
Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods
Harrison, R. P., Zylberberg, E., Ellison, S., & Levine, B. L. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.01.003 · Cited by 96
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
Qu, T., Li, B., & Wang, Y. (2022) · Biomarker Research · doi:10.1186/s40364-022-00373-5 · Cited by 98
Materials for Improving Immune Cell Transfection
Kumar, A. R. K., Shou, Y., Chan, B., Krishaa, L., & Tay, A. K. P. (2021) · Advanced Materials · doi:10.1002/adma.202007421 · Cited by 83
RNA delivery biomaterials for the treatment of genetic and rare diseases
Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82
Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing
Liu, J., Zhou, G., Li, Z., & Zhao, Q. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00456 · Cited by 84
Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity
Li, Y.-R., Brown, J., Yu, Y., Lee, D. P. H., Zhou, K., Dunn, Z. S., Hon, R., Wilson, M., Kramer, A. B., Zhu, Y., et al. (2022) · Cancers · doi:10.3390/cancers14112749 · Cited by 78
A Single-Step Chemoenzymatic Reaction for the Construction of Antibody–Cell Conjugates
Li, J., Chen, M., Liu, Z., Zhang, L., Felding, B. H., Moremen, K. W., Lauvau, G. S., Abadier, M., Ley, K. F., & Wu, P. (2018) · ACS Central Science · doi:10.1021/acscentsci.8b00552 · Cited by 77
Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models
Volpe, A., Lang, C., Lim, L., Man, F., Kurtys, E., Ashmore‐Harris, C., Johnson, P., Skourti, E., de Rosales, R. T. M., & Fruhwirth, G. O. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.028 · Cited by 82
Next-generation drug repurposing using human genetics and network biology
Nabirotchkin, S., Peluffo, A. E., Rinaudo, P., Yu, J., Hajj, R., & Cohen, D. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.12.004 · Cited by 77
Antibody variable region engineering for improving cancer immunotherapy
Lou, H., & Cao, X. (2022) · 癌症：英文版 · doi:10.1002/cac2.12330 · Cited by 78
Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
Kozani, P. S., Kozani, P. S., Najafabadi, M. A., Yousefi, F., Mirarefin, S. M. J., & Rahbarizadeh, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.795164 · Cited by 75
CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
Nasiri, F., Kazemi, M., Mirarefin, S. M. J., Kancha, M. M., Najafabadi, M. A., Salem, F., Shokoohi, S. D., Bakhshi, S. E., Kozani, P. S., & Kozani, P. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018786 · Cited by 78
Nanomaterials for mRNA ‐based therapeutics: Challenges and opportunities
Li, D., Liu, Q., Yang, M., Xu, H., Zhu, M., Zhang, Y., Xu, J., Tian, C., Yao, J., Wang, L., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10492 · Cited by 74
Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy
Perrinjaquet, C., Desbaillets, N., & Hottinger, A. F. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000686 · Cited by 70
Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer
Sur, D. G., Havasi, A. D., Cainap, C. I., Samaşcă, G., Burz, C. C., Bălăcescu, O., Lupan, I., Deleanu, D. M., & Irimie, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010182 · Cited by 67
Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality
Yu, L., Zhang, J., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871076 · Cited by 68
CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities
Akhoundi, M., Mohammadi, M., Sahraei, S. S., Sheykhhasan, M., & Hosseini, N. F. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00593-1 · Cited by 68
CAR T-cells: costs, comparisons, and commentary
Hay, A. E., & Cheung, M. C. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1582059 · Cited by 66
The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy
Liu, D., Badeti, S., Dotti, G., Jiang, J.-G., Wang, H., Dermody, J. J., Soteropoulos, P., Streck, D. L., Birge, R. B., & Liu, C. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00617-7 · Cited by 68
Materials for Cell Surface Engineering
Adebowale, K., Liao, R., Suja, V. C., Kapate, N., Lu, A., Gao, Y., & Mitragotri, S. (2023) · Advanced Materials · doi:10.1002/adma.202210059 · Cited by 64
In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes
Naghizadeh, A., Tsao, W.-C., Cho, J. H., Xu, H., Mohamed, M., Li, D., Xiong, W., Metaxas, D., Ramos, C. A., & Liu, D. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009883 · Cited by 60
Tumor response assessment on imaging following immunotherapy
Berz, A. M., Dromain, C., Violi, N. V., Boughdad, S., & Durán, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.982983 · Cited by 62
Design of a Peptide-Based Electronegative Hydrogel for the Direct Encapsulation, 3D Culturing, in Vivo Syringe-Based Delivery, and Long-Term Tissue Engraftment of Cells
Yamada, Y., Patel, N. L., Kalen, J. D., & Schneider, J. P. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b12152 · Cited by 60
Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages
Li, X., Guo, X., Ling, J., Tang, Z., Huang, G., He, L., & Chen, T. (2021) · Nanoscale · doi:10.1039/d0nr08050k · Cited by 58
Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics
Advani, D., Sharma, S., Kumari, S., Ambasta, R. K., & Kumar, P. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210308101029 · Cited by 63
Peptide Hydrogels as Immunomaterials and Their Use in Cancer Immunotherapy Delivery
Falcone, N., Ermis, M., Tamay, D. G., Mecwan, M. M., Monirizad, M., Mathes, T. G., Jucaud, V., Choroomi, A., de Barros, N. R., Zhu, Y., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301096 · Cited by 60
Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada
Furzer, J., Gupta, S., Nathan, P. C., Schechter, T., Pole, J. D., Krueger, J., & Pechlivanoglou, P. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5909 · Cited by 55
Strategies for Dodging the Obstacles in CAR T Cell Therapy
Kozani, P. S., Kozani, P. S., Rahbarizadeh, F., & Nikkhoi, S. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.627549 · Cited by 57
Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches
Zheng, Y., Nandakumar, K. S., & Cheng, K. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02054 · Cited by 55
The CD47-SIRPα axis is a promising target for cancer immunotherapies
Hao, Y., Zhou, X., Li, Y., Li, B., & Lei, C. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110255 · Cited by 54
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
Guha, A., Armanious, M. A., & Fradley, M. G. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.001 · Cited by 54
Redox Electrochemistry to Interrogate and Control Biomolecular Communication
VanArsdale, E. S., Pitzer, J., Payne, G. F., & Bentley, W. E. (2020) · iScience · doi:10.1016/j.isci.2020.101545 · Cited by 52
RETRACTED: A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions
Marofi, F., Rahman, H. S., Achmad, M. H., Sergeevna, K. N., Suksatan, W., Abdelbasset, W. K., Mikhailova, M. V., Shomali, N., Yazdanifar, M., Hassanzadeh, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.681984 · Cited by 48
Retracted
Peptide Delivery Systems for Cancer Vaccines
He, X., Abrams, S. I., & Lovell, J. F. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800060 · Cited by 45
T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances
Lin, Y., & Wang, J. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02867-6 · Cited by 43
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19
Sharun, K., Tiwari, R., Yatoo, M. I., Natesan, S., Megawati, D., Singh, K. P., Michalak, I., & Dhama, K. (2022) · Narra J · doi:10.52225/narra.v2i3.92 · Cited by 42
T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts
Nasiri, F., Kozani, P. S., & Rahbarizadeh, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1063838 · Cited by 42
Novel antigens of CAR T cell therapy: New roads; old destination
Kozani, P. S., Kozani, P. S., & Rahbarizadeh, F. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101079 · Cited by 45
Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies
Truong, N. T., Gargett, T., Brown, M. P., & Ebert, L. M. (2021) · Cancers · doi:10.3390/cancers13092225 · Cited by 47
Immunotherapy approaches for the treatment of diffuse midline gliomas
Bernstock, J. D., Hoffman, S. E., Kappel, A. D., Valdes, P. A., Essayed, W. I., Klinger, N. V., Kang, K., Totsch, S. K., Olsen, H. E., Schlappi, C., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2124058 · Cited by 41
Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse
Liu, L., Ma, C., Zhang, Z., Witkowski, M. T., Aifantis, I., Ghassemi, S., & Chen, W. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005360 · Cited by 40
The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies
Fruhwirth, G. O., Kneilling, M., de Vries, I. J. M., Weigelin, B., Srinivas, M., & Aarntzen, E. H. J. G. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-018-1254-3 · Cited by 42
Sniping Cancer Stem Cells with Nanomaterials
Wang, W.-D., Guo, Y., Yang, Z., Su, G.-L., & Sun, Z. (2023) · ACS Nano · doi:10.1021/acsnano.3c07828 · Cited by 38
Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodies
Najafi, S., & Mortezaee, K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122387 · Cited by 39
Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies
Weisbrod, L. J., Anand, T., Vengoji, R., Shonka, N., Jain, M., Ho, W. S., Batra, S. K., & Salehi, A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216876 · Cited by 44
Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics
Scheller, J., Engelowski, E., Moll, J. M., & Floss, D. M. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.01.001 · Cited by 37
Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma
Ren, L., Leisegang, M., Deng, B., Matsuda, T., Kiyotani, K., Kato, T., Harada, M., Park, J., Saloura, V., Seiwert, T. Y., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1568813 · Cited by 36
Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?
Jiang, H., Hu, Y., & Mei, H. (2020) · Biomarker Research · doi:10.1186/s40364-020-00247-8 · Cited by 38
mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells
Jayasooriya, V., Ringwelski, B., Dorsam, G. P., & Nawarathna, D. (2021) · Lab on a Chip · doi:10.1039/d1lc00219h · Cited by 34
Flow Cytometric Monitoring for Residual Disease in B Lymphoblastic Leukemia Post T Cell Engaging Targeted Therapies
Cherian, S., & Stetler‐Stevenson, M. (2018) · Current Protocols in Cytometry · doi:10.1002/cpcy.44 · Cited by 34
Immunotherapies and immunomodulatory approaches in clinical trials - a mini review
Yatoo, M. I., Hamid, Z., RATHER, I. A., Nazir, Q. U. A., Bhat, R. A., Haq, A. U., Magray, S. N., Haq, Z. U., Sah, R., Tiwari, R., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1871295 · Cited by 36
Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward
Kozani, P. S., Kozani, P. S., & Rahbarizadeh, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.765097 · Cited by 37
Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas
Noon, A., & Galbán, S. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100899 · Cited by 38
Scaffold‐Mediated Static Transduction of T Cells for CAR‐T Cell Therapy
Agarwalla, P., Ogunnaike, E. A., Ahn, S., Ligler, F. S., Dotti, G., & Brudno, Y. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000275 · Cited by 32
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells
Dwivedi, A., Karulkar, A., Ghosh, S., Srinivasan, S., Kumbhar, B. V., Jaiswal, A. K., Kizhakeyil, A., Asija, S., Rafiq, A., Kumar, S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0476 · Cited by 35
Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A Cost-Effectiveness Analysis
Kelkar, A. H., Cliff, E. R. S., Jacobson, C. A., Abel, G. A., Dijk, S. W., Krijkamp, E. M., Redd, R., Zurko, J. C., Hamadani, M., Hunink, M. G. M., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2276 · Cited by 31
Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer
Chu, W., Zhou, Y., Tang, Q., Wang, M., Ji, Y., Yan, J., Yin, D., Zhang, S., Lu, H., & Shen, J. (2018) · BioScience Trends · doi:10.5582/bst.2018.01048 · Cited by 32
A Comprehensive Review of Recent Advancements in Cancer Immunotherapy and Generation of CAR T Cell by CRISPR-Cas9
Saber, M. A., Biswas, P., Dey, D., Kaium, M. A., Islam, M. A., Tripty, M. I. A., Rahman, M. H., Rahaman, T. I., Biswas, M. Y., Paul, P., et al. (2021) · Processes · doi:10.3390/pr10010016 · Cited by 37
Prediction of Gold Nanoparticle and Microwave-Induced Hyperthermia Effects on Tumor Control via a Simulation Approach
Dimitriou, N. M., Pavlopoulou, A., Tremi, I., Kouloulias, V., Tsigaridas, G., & Georgakilas, A. G. (2019) · Nanomaterials · doi:10.3390/nano9020167 · Cited by 30
Nucleic Acid Immunotherapeutics for Cancer
Shen, T., Zhang, Y., Zhou, S., Lin, S., Zhang, X., & Zhu, G. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00101 · Cited by 32
Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments
Nix, M. A., & Wiita, A. P. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.02.024 · Cited by 30
The biology and therapeutic management of melanoma brain metastases
Abate‐Daga, D., Ramello, M. C., Smalley, I., Forsyth, P. A., & Smalley, K. S. M. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.12.019 · Cited by 30
A Drug-Tunable Gene Therapy for Broad-Spectrum Protection against Retinal Degeneration
Santiago, C. P., Keuthan, C. J., Boye, S. L., Boye, S. L., Imam, A. A., & Ash, J. D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.016 · Cited by 29

Authors: Prasad, V.
Affiliations: Oregon Health & Science University (US)
Corresponding author: Prasad, Vinay
ORCID: Prasad, Vinay
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2017-10-04
Volume: 15
Issue: 1
Pages: 11-12
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2017.156
OpenAlex: W2761202053
Cited by: 229
References: 5
Citations by year: 2026: 17 · 2025: 12 · 2024: 27 · 2023: 28 · 2022: 36 · 2021: 31 · 2020: 28 · 2019: 25 · 2018: 24 · 2017: 1
FWCI: 9.40
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
Keywords: tisagenlecleucel, CAR T-cell therapy, FDA approval, health care costs, drug pricing, health policy, health insurance coverage, treatment toxicity, healthcare logistics
MeSH terms: Receptors, Chimeric Antigen, Humans, Immunotherapy, Neoplasms, Receptors, Antigen, T-Cell, Immunotherapy, Adoptive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks